Preproglucagon neurons in the nucleus of the solitary tract are the main source of brain GLP-1, mediate stress-induced hypophagia, and limit unusually large intakes of food
On May 2, 2026, The Lancet published a randomized, double-blind, placebo-controlled trial (Klausen et al., Copenhagen University Hospital) testing once-weekly semaglutide 2.4 mg in 108 treatment-seeking adults with moderate to severe alcohol use disorder and comorbid obesity
Its triple receptor activity makes it particularly valuable for mechanistic investigations involving glucose regulation, nutrient utilization, metabolic flexibility, and energy expenditure
The telehealth company Hims, which has sold branded and compounded GLP-1s, recently announced plans to offer a cheaper pill form of the GLP-1